This, in combination with the reduction in cell viability, induction of DNA damage and increased apoptosis following defactinib and dasatinib combination treatment in DSRCT, ERMS, and ARMS cells showed that targeting of the FAK-Src complex could enhance the antitumor effect in these sarcoma subtypes. The gene discussed is SRC; the disease is sarcoma.